International ClinicsMedical News
International Clinics Newsroom · · 1 min read
Daily

FDA approves asundexian, the first factor XIa inhibitor to prevent repeat stroke

  • On 9 November 2026 the FDA approved Bayer's Sunharbo (asundexian).
  • It is for adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk TIA.
  • In OCEANIC-STROKE (12,327 patients) ischemic stroke fell to 6.2% vs 8.4% with placebo.
  • Major bleeding was similar: 1.9% vs 1.7%.
Brain scan showing its blood vessels
Brain scan showing its blood vessels Photo: AJMC
Published:

The US Food and Drug Administration approved Sunharbo (asundexian), made by Bayer, on 9 November 2026. It is the first approved activated factor XI (XIa) inhibitor. It lowers the risk of another stroke in adults after a mild-to-moderate ischemic stroke that did not come from the heart, or after a high-risk transient ischemic attack.

What the trial showed

Approval rests on OCEANIC-STROKE, which enrolled 12,327 patients taking 50 mg once daily on top of standard antiplatelet therapy. Ischemic stroke occurred in 6.2% on asundexian versus 8.4% on placebo: about a 26% relative and 2.2% absolute reduction.

Bleeding

Major bleeding was similar (1.9% vs 1.7%), which matters because bleeding is the main worry with drugs that prevent clotting. Diarrhea was reported in 3.4% vs 2.8%.

Limits

The drug is not approved for atrial fibrillation and is used with antiplatelet therapy, not instead of it. Experts note its list price of about $748.50 a month may limit uptake.

Sources: FDA — Novel Drug Approvals 2026, AJMC, NeurologyLive

This story is relayed from the source named above; responsibility for its content rests with the original source.

FAQ

What is asundexian (Sunharbo)?

Asundexian is an oral drug from Bayer and the first activated factor XI (XIa) inhibitor approved by the FDA, used to lower the risk of a repeat stroke.

Who is asundexian for?

Asundexian is for adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk TIA, taken together with antiplatelet therapy.

How much did asundexian reduce stroke?

In OCEANIC-STROKE, ischemic stroke occurred in 6.2% of patients on asundexian versus 8.4% on placebo, a relative reduction of about 26%.

Does asundexian raise bleeding risk?

In OCEANIC-STROKE, major bleeding was similar: 1.9% with asundexian versus 1.7% with placebo.

Is asundexian approved for atrial fibrillation?

No. The FDA approval of asundexian does not cover patients with atrial fibrillation.

How would you rate this story?
135
Latest news
A fluoride-free gel that may rebuild tooth enamel, from the University of Nottingham Jackson 5's Marlon Jackson reveals he has lived with prostate cancer for four years Tip of the day: get your flu vaccine early, before winter peaks Every plant-based food in a UK study contained fungal toxins, all within EU guideline levels Tip of the day: spit, don't rinse, after brushing your teeth Energy drinks appear 11 times more often in cardiac arrest reports, preliminary study finds ISAPS global survey: eyelid surgery leads, breast lift grows fastest and filler declines Hippocrates: "Life is short, and Art long" Born on this day: William Beaumont and the hole in a stomach that rewrote digestion Tip of the day: sleep at least 7 hours a night, on a regular schedule
The latest-news bar is closed. You can bring it back any time with the “Latest news” button in the menu.